Geoffrey McDonough - Swedish Orphan Insider

Swedish Orphan Biovitrum AB -- USA Stock  

USD 18.52  0.0002  0.0011%

CEO

Dr. Geoffrey McDonough, M.D. no longer serves as President and Chief Executive Officer of Swedish Orphan Biovitrum AB effective as of July 1, 2017. He has held the position since August 15, 2011. He is also Board member of Zafgen and PTC Therapeutics. He previously served for Genzyme Corporationrationration in the United States from 2002, where he has over the years held such roles as Senior Vice President and General Manager, Personalized Genetic Health Senior Vice President, Global Business Unit Leader, LSD Therapeutics, and most recently, President of Europe, Middle East, and Africa . Prior to joining Genzyme, he worked as a pediatrician in the United States, and was also President, and Cofounder of Catalyst Medical Solutions Inc. He graduated from Harvard Medical School with a Medical Doctor degree. He holds a Bachelor of Arts in Philosophy and a BS in Biology degrees from the University of North Carolina.
Age: 44  CEO Since 2011  Ph.D    
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 9.59 % which means that it generated profit of $9.59 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 19.06 % meaning that it generated $19.06 on every $100 dollars invested by stockholders.
The company has accumulated 833.91 K in total debt with debt to equity ratio (D/E) of 0.1 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.72 which is within standard range for the sector.

Similar Executives

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 800 people.

Swedish Orphan Biovi Leadership Team

Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance Indicators

Current Sentiment - BIOVF

Swedish Orphan Biovi Investor Sentiment
Macroaxis portfolio users are unresponsive in their opinion about investing in Swedish Orphan Biovitrum AB. What is your outlook on investing in Swedish Orphan Biovitrum AB? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

BATS Exchange Efficient Frontier

Diversify in USA Market
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
Diversify Portfolios
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1) For any level of risk, select the one which has the highest expected return. 2) For any expected return, select the one which has the lowest volatility.
Diversify Portfolios
Check also Trending Equities. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.